Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: david wolf who wrote (152)	5/21/1998 9:12:00 AM
From: JOEBT1	Respond to of 668

David--I also talked to IR recently.I asked if they had any views on why the stock price has been so weak. She said that right after the report on trial results, an institution started selling their holdings which accelerated the decline. On May 15 Solomen/Smith Barney dropped their buy recommendation on CBMI and stopped their coverage of CBMI because the analyst following CBMI went to J P Morgan. This probably contributed to recent weakness. Stryker is aggressively pursuing additional trials using OP-1 for acute fractures (200 patients) and peridontal disease. Stryker is keeping these trials and others under wraps because of competitive reasons. Reportedly the Biogen partnership is going well and they expect it to be continued. As indicated in a another post they have already filed half the info to the FDA and will soon complete the filing. I bought more CBMI after the discussion. FWIW--no guarantees on above.